William E. Fisher
YOU?
Author Swipe
View article: Prostaglandin E2 as a Mechanistic Biomarker of Chronic Pancreatitis
Prostaglandin E2 as a Mechanistic Biomarker of Chronic Pancreatitis Open
INTRODUCTION: Chronic pancreatitis (CP) is a disease associated with chronic inflammation, fibrosis, and pain. There is a lack of tools available that facilitate early diagnosis, when intervention could prevent irreversible damage. Pilot d…
View article: Histologic- and Genomic-Directed Adjuvant Therapy for Ampullary Adenocarcinoma: A Hidden Genome–Derived Analysis
Histologic- and Genomic-Directed Adjuvant Therapy for Ampullary Adenocarcinoma: A Hidden Genome–Derived Analysis Open
Background: The benefit of adjuvant chemotherapy (AC) for ampullary adenocarcinoma is unclear. The Hidden Genome model classifies prognostic subtypes with greater accuracy than standard histologic classification (intestinal [INT] vs pancre…
View article: Prevalence and Patterns of Opioid Use in Chronic Pancreatitis
Prevalence and Patterns of Opioid Use in Chronic Pancreatitis Open
INTRODUCTION: Opioids are used to treat pain in chronic pancreatitis (CP), but little is known about current use patterns. The aim of this study was to characterize the utilization of opioids and associations with clinical characteristics …
View article: Use of pancreatic endotherapy in patients with chronic pancreatitis: results from a multicenter cohort study in the United States
Use of pancreatic endotherapy in patients with chronic pancreatitis: results from a multicenter cohort study in the United States Open
View article: Circulating immune signatures in chronic pancreatitis with and without preceding acute pancreatitis: A pilot study
Circulating immune signatures in chronic pancreatitis with and without preceding acute pancreatitis: A pilot study Open
View article: Circulating immune signatures across clinical stages of chronic pancreatitis: a pilot study
Circulating immune signatures across clinical stages of chronic pancreatitis: a pilot study Open
Objective This pilot study seeks to identify serum immune signatures across clinical stages of patients with chronic pancreatitis (CP). Methods We performed a cross-sectional analysis of prospectively collected serum samples from the PROsp…
View article: Nanoparticle-Mediated Therapy with miR-198 Sensitizes Pancreatic Cancer to Gemcitabine Treatment through Downregulation of VCP-Mediated Autophagy
Nanoparticle-Mediated Therapy with miR-198 Sensitizes Pancreatic Cancer to Gemcitabine Treatment through Downregulation of VCP-Mediated Autophagy Open
Pancreatic ductal adenocarcinoma (PDAC) remains an extremely aggressive disease characterized by rapidly acquired multi-drug resistance, including to first-line chemotherapeutic agent gemcitabine. Autophagy is a process that is often explo…
View article: Serum Biomarkers of Nociceptive and Neuropathic Pain in Chronic Pancreatitis
Serum Biomarkers of Nociceptive and Neuropathic Pain in Chronic Pancreatitis Open
View article: Supplementary Fig. S2 from Enhancing the Potency and Specificity of Engineered T Cells for Cancer Treatment
Supplementary Fig. S2 from Enhancing the Potency and Specificity of Engineered T Cells for Cancer Treatment Open
Differential gene expression profile of SmarT-cells vs CAR T cells
View article: Supplementary Fig. S6 from Enhancing the Potency and Specificity of Engineered T Cells for Cancer Treatment
Supplementary Fig. S6 from Enhancing the Potency and Specificity of Engineered T Cells for Cancer Treatment Open
Levels of IL4 and TGFβ cytokines produced by CAPAN-1 PSCA/TGFβ/IL4 cell line
View article: Supplementary Fig. S5 from Enhancing the Potency and Specificity of Engineered T Cells for Cancer Treatment
Supplementary Fig. S5 from Enhancing the Potency and Specificity of Engineered T Cells for Cancer Treatment Open
SmarT-cells isolated from CAPAN-1 PSCA/TGFβ/IL4 expressing tumors in mice contain both CD4+ and CD8+ T cell fractions
View article: Supplementary Tables 1-5 from Enhancing the Potency and Specificity of Engineered T Cells for Cancer Treatment
Supplementary Tables 1-5 from Enhancing the Potency and Specificity of Engineered T Cells for Cancer Treatment Open
Consolidated supplementary tables for nanostring data
View article: Supplementary Tables 1-5 from Enhancing the Potency and Specificity of Engineered T Cells for Cancer Treatment
Supplementary Tables 1-5 from Enhancing the Potency and Specificity of Engineered T Cells for Cancer Treatment Open
Consolidated supplementary tables for nanostring data
View article: Supplementary Fig. S4 from Enhancing the Potency and Specificity of Engineered T Cells for Cancer Treatment
Supplementary Fig. S4 from Enhancing the Potency and Specificity of Engineered T Cells for Cancer Treatment Open
TNF alpha and IFN gamma levels from CD4+ and CD8+ sorted SmarT-cells
View article: Supplementary Fig. S2 from Enhancing the Potency and Specificity of Engineered T Cells for Cancer Treatment
Supplementary Fig. S2 from Enhancing the Potency and Specificity of Engineered T Cells for Cancer Treatment Open
Differential gene expression profile of SmarT-cells vs CAR T cells
View article: Supplementary Fig. S3 from Enhancing the Potency and Specificity of Engineered T Cells for Cancer Treatment
Supplementary Fig. S3 from Enhancing the Potency and Specificity of Engineered T Cells for Cancer Treatment Open
Selective enrichment process of CAR- and CAR+ transgenic sub-populations
View article: Data from Enhancing the Potency and Specificity of Engineered T Cells for Cancer Treatment
Data from Enhancing the Potency and Specificity of Engineered T Cells for Cancer Treatment Open
The adoptive transfer of chimeric antigen receptor (CAR)–modified T cells has produced tumor responses even in patients with refractory diseases. However, the paucity of antigens that are tumor selective has resulted, on occasion, in “on-t…
View article: Supplementary Fig. S1 from Enhancing the Potency and Specificity of Engineered T Cells for Cancer Treatment
Supplementary Fig. S1 from Enhancing the Potency and Specificity of Engineered T Cells for Cancer Treatment Open
PSCA, TGFβ and IL4 overexpression at the pancreatic tumor site
View article: Supplementary Fig. S5 from Enhancing the Potency and Specificity of Engineered T Cells for Cancer Treatment
Supplementary Fig. S5 from Enhancing the Potency and Specificity of Engineered T Cells for Cancer Treatment Open
SmarT-cells isolated from CAPAN-1 PSCA/TGFβ/IL4 expressing tumors in mice contain both CD4+ and CD8+ T cell fractions
View article: Data from Enhancing the Potency and Specificity of Engineered T Cells for Cancer Treatment
Data from Enhancing the Potency and Specificity of Engineered T Cells for Cancer Treatment Open
The adoptive transfer of chimeric antigen receptor (CAR)–modified T cells has produced tumor responses even in patients with refractory diseases. However, the paucity of antigens that are tumor selective has resulted, on occasion, in “on-t…
View article: Supplementary Fig. S6 from Enhancing the Potency and Specificity of Engineered T Cells for Cancer Treatment
Supplementary Fig. S6 from Enhancing the Potency and Specificity of Engineered T Cells for Cancer Treatment Open
Levels of IL4 and TGFβ cytokines produced by CAPAN-1 PSCA/TGFβ/IL4 cell line
View article: Supplementary Fig. S1 from Enhancing the Potency and Specificity of Engineered T Cells for Cancer Treatment
Supplementary Fig. S1 from Enhancing the Potency and Specificity of Engineered T Cells for Cancer Treatment Open
PSCA, TGFβ and IL4 overexpression at the pancreatic tumor site
View article: Supplementary Fig. S3 from Enhancing the Potency and Specificity of Engineered T Cells for Cancer Treatment
Supplementary Fig. S3 from Enhancing the Potency and Specificity of Engineered T Cells for Cancer Treatment Open
Selective enrichment process of CAR- and CAR+ transgenic sub-populations
View article: Supplementary Fig. S4 from Enhancing the Potency and Specificity of Engineered T Cells for Cancer Treatment
Supplementary Fig. S4 from Enhancing the Potency and Specificity of Engineered T Cells for Cancer Treatment Open
TNF alpha and IFN gamma levels from CD4+ and CD8+ sorted SmarT-cells
View article: Supplementary Figure 3 from A Tumorigenic Factor Interactome Connected through Tumor Suppressor MicroRNA-198 in Human Pancreatic Cancer
Supplementary Figure 3 from A Tumorigenic Factor Interactome Connected through Tumor Suppressor MicroRNA-198 in Human Pancreatic Cancer Open
Supplementary Figure 3 - PDF file 142K, miR-198 modulation in stable cell lines
View article: Data from Specific Targeting of Somatostatin Receptor Subtype-2 for Fluorescence-Guided Surgery
Data from Specific Targeting of Somatostatin Receptor Subtype-2 for Fluorescence-Guided Surgery Open
Purpose:Clinically available intraoperative imaging tools to assist surgeons in identifying occult lesions are limited and partially responsible for the high rate of disease recurrence in patients with neuroendocrine tumors (NET). Using th…
View article: Supplementary Data from Specific Targeting of Somatostatin Receptor Subtype-2 for Fluorescence-Guided Surgery
Supplementary Data from Specific Targeting of Somatostatin Receptor Subtype-2 for Fluorescence-Guided Surgery Open
Supplementary figures and tables. "Clean" version.
View article: Data from Mesothelin is a malignant factor and therapeutic vaccine target for pancreatic cancer
Data from Mesothelin is a malignant factor and therapeutic vaccine target for pancreatic cancer Open
Given the high fatality rate of pancreatic cancer, an effective treatment for this devastating disease is urgently needed. We have shown that mesothelin expression was higher in human pancreatic cancer cells than in human pancreatic duct e…
View article: Data from Down-regulation of ZIP4 by RNA Interference Inhibits Pancreatic Cancer Growth and Increases the Survival of Nude Mice with Pancreatic Cancer Xenografts
Data from Down-regulation of ZIP4 by RNA Interference Inhibits Pancreatic Cancer Growth and Increases the Survival of Nude Mice with Pancreatic Cancer Xenografts Open
Purpose: Zinc levels have been correlated with cancer risk, although the role of zinc and zinc transporters in cancer progression is largely unknown. We recently found that a zinc transporter, ZIP4, is overexpressed in pancreatic ca…
View article: Data from Specific Targeting of Somatostatin Receptor Subtype-2 for Fluorescence-Guided Surgery
Data from Specific Targeting of Somatostatin Receptor Subtype-2 for Fluorescence-Guided Surgery Open
Purpose:Clinically available intraoperative imaging tools to assist surgeons in identifying occult lesions are limited and partially responsible for the high rate of disease recurrence in patients with neuroendocrine tumors (NET). Using th…